PAK5与乳腺癌分子分型及临床病理特征的相关性分析

Correlations of PAK5 withmolecular subtypes and clinicopathological parametersof breast cancer

目的探讨PAK5表达与乳腺癌分子分型及临床病理特征的相关性。方法采用免疫组化法检测乳腺癌组织中PAK5、ER、PR、HER2、Ki-67表达并评分,应用荧光原位杂交(fluorescence in situ hybridization,FISH)进一步检测免疫组化HER22+的乳腺癌组织中HER2基因扩增情况,分析PAK5表达与乳腺癌分子分型、TNM分期、肿块大小、淋巴结转移等的关系。结果根据HER2基因有无扩增分别纳入HER2阳性组和阴性组。与癌旁组织相比,PAK5在乳腺癌组织中的表达增加;PAK5高表达与患者肿块较大、淋巴结转移、TNM高分期等呈正相关(P<0.05);PAK5高表达与患者生存率低相关(P<0.05);PAK5表达与ER、PR表达呈负相关,与Ki-67表达呈正相关(P<0.05);与非三阴型乳腺癌相比,PAK5在三阴型乳腺癌中的表达增加,差异有统计学意义(P<0.05)。结论PAK5在乳腺癌组织中的表达增加,且与乳腺癌分子分型、TNM分期及不良预后密切相关,PAK5有望成为临床治疗乳腺癌的新靶点。

Purpose To investigated the correlation between PAK5 expression,molecular subtypes and the clinical parameter of breast cancer.Methods The expression of PAK5,ER,PR,HER2,Ki-67 in sample tissues was detected and scored by immunohistochemistry.In addition,fluorescence in situ hybridization(FISH)was used to further detect the HER2 gene amplification in breast cancer tissues of HER2 IHC 2+.The relationship of PAK5 with molecularsubtypes,TNM stage,tumor size and lymphatic metastasis of breast cancers were performedby utilizing SPSS and statistical analysis.Results According to the amplification of HER2 genes,they are divided into HER2 positive group and negative group.PAK5 in breast carcinoma was significantly higher than normal amount ofexpression in tumor adjacent tissues.High PAK5 expression was positively correlatedwith largertumor size,lymphatic metastasis and advanced TNM stage in patients,as well as with worse overallsurvival(P<0.05).PAK5 was negatively correlated with ER and PR(P<0.05).Beside,PAK5 was positively correlated with Ki-67(P<0.05).PAK5 expression in triple negative breast cancer was higher than that in the other types of breast cancer,while there was significant difference(P<0.05).Conclusion PAK5 is over-expressed in human breast carcinoma tissue.High expression of PAK5 is significantly associated with breast cancer molecular subtype,advanced TNM stage and worse overall survival of breast carcinoma patients.Therefore,PAK5 may provide novel therapeutic targets for the future treatment of breast carcinoma.